Kypha develops tests for monitoring immune status and inflammation, while Biosensia's RapiPlex system can run simultaneous multiplex testing up to 24 analytes.
Dendritics develops antibodies against immune system and other cells for the discovery of targets with high diagnostic, prognostic, and therapeutic potential.
NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.